Sifalimumab

A4DAB239 | Phase-II

Target IFNA1

Isotype / Subclass G1 / None

Company

Medarex MedImmune

Clinical Status Phase-II

Format Whole mAb

Synonyms

MDX-1103 MDX1103 MDX 1103 MEDI-545 MEDI545 MEDI 545

pH Formulation —

IMGT PubChem (135309420) PubChem (160682615) PubChem (249565937) PubChem (347911377) PubChem (472220432) PubChem (472422558) PubChem (472435542) PubChem (472440374) PubChem (481155533) PubChem (498156033) PubChem (505880970) Thera-SAbDab YAbS

Avg A4D Score

-0.6825

Score Range

-0.69 to -0.68

Structures

2

Avg. A4D Score per Structure

pH at Min / Max Aggregation Propensity

Structure ID	Source PDB	Seq. Identity	Avg. A4D Score	pH (Min Agg.)	pH (Max Agg.)	Score CDR	Score non-CDR
A4DAB239_4ypg_B_A	4ypg	100%	-0.6775	6.5	4.0	-0.2702	-0.7234
A4DAB239_4ypg_H_L	4ypg	100%	-0.6874	6.5	4.0	-0.2766	-0.7337

Sifalimumab

Avg. A4D Score per Structure

pH at Min / Max Aggregation Propensity

Associated Structural Profiles Level 2